SAMANTHA BOREN: Open Payments
NPI 1245910298 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$518 in 34 payments from 8 companies in 2025. Trend: 2023 $52 · 2024 $229 · 2025 $518
Food & beverage: $491Education: $27
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $175 |
| ABBVIE INC. | 14 | $141 |
| E.R. Squibb & Sons, L.L.C. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: CAPLYTA, VRAYLAR, COBENFY, REXULTI, FANAPT, Auvelity, UZEDY, Qelbree.
Industry payments across MS — which companies pay providers there.
